Saudi Arabia Aims to Lead Global Biotechnology with Ambitious 20-Year Plan
Saudi Arabia has set its sights on becoming a global leader in biotechnology, with the National Biotechnology Strategy launched in January 2024. The ambitious plan aims to contribute $34.6 billion annually to the Kingdom’s non-oil GDP by 2040, creating 11,000 jobs by 2030 and 55,000 by 2040. The strategy focuses on four key pillars: vaccines, biomanufacturing, genomics, and agricultural biotechnology, with a short-term emphasis on medical biotechnology due to the high prevalence of genetic diseases in the country.
The strategy includes five enabling factors: sustainable talent, infrastructure, regulatory excellence, strategic funding, and geographic location. Saudi Arabia is following a development path similar to Singapore’s, where government demand drives initial growth, gradually shifting to organic development. The Kingdom has already made significant progress in regulation, with the Saudi Food and Drug Authority (SFDA) achieving the highest possible maturity level in October 2023.
Research and clinical capabilities are also advancing, with the approval of CASGEVY, a CRISPR gene-editing drug, in January 2024. The Saudi Biobank has recruited over 53,000 participants and collected nearly 590,000 biospecimens by mid-2024. However, manufacturing remains the least mature initiative, with the first biopharmaceutical production units now under construction. Investment in venture capital funding is another gap, despite the pharmaceuticals market growing at over seven percent annually.
Partnerships with international biotech companies, such as Flashpoint Therapeutics and Flagship Pioneering, highlight the mutual benefits of knowledge exchange and patient access. However, the challenge lies in ensuring that Saudi Arabia not only hosts science but also owns it. The availability of talent is crucial, with educational programs at King Saud bin Abdulaziz University for Health Sciences (KSAU-HS) focusing on science, business, and data to build a robust biotechnology workforce.